Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
neuroaxpharm
Mississauga, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuroAxon was a clinical-stage biotechnology company focused on the development of next-generation pain therapeutics. The company's primary focus was on the discovery and development of selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme implicated in the transmission of pain signals. Its lead candidate, NXN-188, was evaluated in Phase 2 clinical trials for the treatment of acute migraine and other pain conditions. Despite promising early data, the company faced challenges in later-stage development and eventually ceased operations, with its intellectual property being liquidated or licensed.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Vernalis
Beyond the preview
Go deeper on neuroaxpharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neuroaxpharm.